Pier Capital, LLC Apellis Pharmaceuticals, Inc. Transaction History

Pier Capital, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 10, 2023	BUY	$46.59 - $66.96 $39,554 - $56,849	849 Added 1.13%	76,066 $5.02 Million
Q4 2022 Feb 15, 2023	BUY	$43.24 - $61.04 $857,578 - $1.21 Million	19,833 Added 35.81%	75,217 $3.89 Million
Q3 2022 Nov 15, 2022	SELL	$44.76 - $69.66 $3.36 Million - $5.22 Million	-74,956 Reduced 57.51%	55,384 $3.78 Million
Q2 2022 Aug 15, 2022	BUY	$35.07 - $59.21 $4,629 - $7,815	132 Added 0.1%	130,340 $5.89 Million
Q1 2022 May 10, 2022	SELL	$35.46 - $54.12 $3.25 Million - $4.96 Million	-91,693 Reduced 41.32%	130,208 $6.62 Million
Q4 2021 Feb 10, 2022	BUY	$30.74 - $49.16 $2.02 Million - $3.24 Million	65,870 Added 42.22%	221,901 $10.5 Million
Q3 2021 Nov 10, 2021	BUY	$31.4 - $69.84 $4.9 Million - $10.9 Million	156,031 New	156,031 $5.14 Million

301

111M

2.63M

845K

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $2.67B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of Pier Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Pier Capital, LLC with notifications on news.